Investigating the effectiveness of methylphenidate and combination of magnesium and zinc and calcium in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City
Phase 2
- Conditions
- Attention deficit hyperactivity disorder (ADHD).Disturbance of activity and attention
- Registration Number
- IRCT2015092624209N1
- Lead Sponsor
- Vice Chancellor for Research and Technology at Zahedan University of Medical Sciences and Health Ser
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Aged 6 to 12 years; diagnosis of attention deficit hyperactivity disorder (ADHD) based on DSM-IV-TR diagnostic criteria; the scale to measure attention deficit hyperactivity disorder (ADHD) in parent and teacher form, at least 20.
Exclusion criteria: Any simultaneous major psychiatric disease, except confrontational behavior and learning disorder; IQ less than 70; the use of psychotropic drugs or narcotic materials in the past two weeks; any important neurological diseases; taking any drug affecting the nervous system, at least two weeks prior to the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Medication. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after intervention. Method of measurement: Attention deficit hyperactivity disorder (ADHD) Rating Scale.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after intervention. Method of measurement: Attention deficit hyperactivity disorder (ADHD) Rating Scale.;Disorder severity. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after intervention. Method of measurement: Attention deficit hyperactivity disorder (ADHD) Rating Scale.